300+ investors in your industry, stage, and region Get
Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Retail
Oil and Gas
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Fitness
Organic Food
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Blockchain
Facebook
B2B
Social Network
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Theatre
Medical
Recruiting
Web3
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Music
Art
Real Estate
Sporting Goods
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Burkina Faso
Oman
Puerto Rico
Poland
Cameroon
Guernsey
Sudan
Andorra
Colombia
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Moldova
Botswana
Seychelles
Paraguay
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
Canada
United States
United Kingdom
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Argentina
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Slovenia
Peru
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Li Ka-shing, Founder and Chairman at Horizons Ventures

Li Ka-shing

Founder and Chairman @ Horizons Ventures

Hong Kong, Hong Kong

Li Ka-shing is a Series A investor at Horizons Ventures in Hong Kong focused on Health Care and Biotechnology. Mr. Li Ka-shing is the richest person of East Asian descent in the world and the 11th richest person in the world with an estimated wealth of US$26 billion (as estimated by Forbes). His primary operating company is Hutchison Whampoa Limited. Mr Li's younger son, Richard, is Chairman of PCCW, one of Asia's leading internet andtelecommunications companies.Mr Li Ka-shing is the Chairman of Cheung Kong (Holdings) Limited and Hutchison Whampoa Limited. Cheung Kong (Holdings) Limited is the flagship of the Cheung Kong Group which has business operations in 54 countries around the world and employs about 240,000 staff. In Hong Kong alone, the Group includes nine listed companies with a combined market capitalization of approximately HKD600 billion (30 June 2009). Hutchison Whampoa Limited is a Fortune Global 500 company.Born in 1928 in Chiu Chow, a coastal city in the southeastern part of China, Mr Li fled to Hong Kong with his family to avoid the perils of war. His father suffered from tuberculosis and passed away in Hong Kong. Shouldering the responsibility of looking after the livelihood of the family, Mr Li was forced to leave school before the age of 15 and found a job in a plastics trading company where he labored 16 hours a day. By 1950, his hard work, prudence and his pursuit of excellence had enabled him to start his own company, Cheung Kong Industries. From manufacturing plastics, Mr Li led and developed his company into a leading real estate investment company in Hong Kong that was listed on the Hong Kong Stock Exchange in 1972. Cheung Kong continued to expand by acquiring Hutchison Whampoa and Hongkong Electric Holdings Limited in 1979 and 1985 respectively.Based in Hong Kong, the Cheung Kong Group's businesses encompass such diverse areas as property development and investment, real estate agency and estate management, hotels, telecommunications and e-commerce, finance and investments, retail, ports and related services, energy, infrastructure projects and materials, media, and biotechnology. Mr Li is a strong believer in synergy — the power of combined efforts. This belief is reflected in his naming his company Cheung Kong Holdings after the Yangtze River that flows through China, a great river that aggregates countless streams and tributaries. The Times in the United Kingdom and Ernst & Young UK jointly named Mr Li as the Entrepreneur of the Millennium at the turn of the century.http://www.hutchison-whampoa.com/eng/about/chairman/chairman.htm 30 June 2009

Total investments:
27
Last investment:
Lead investor:
41%

Last updated:

Industries Li Ka-shing invests in

Health CareBiotechnologyMedical DeviceFood and BeverageiOS

Stages Li Ka-shing invests in

Series ASeries BSeedSeries CSeries D

Countries Li Ka-shing invests in

United StatesUnited KingdomIsraelCanadaSweden

Round sizes

Seed $300k–$11MSeries A $21M–$50MSeries B $15M–$50M

Round size

Seed
$300k–$11M
Series A
$21M–$50M
Series B
$15M–$50M

Investment Focus

Industry

  • Health Care 5 (19%)
  • Biotechnology 4 (15%)
  • Medical Device 3 (11%)
  • Food and Beverage 3 (11%)
  • iOS 2 (7%)
See all 63 industries →

Stage

  • Series A 5 (19%)
  • Series B 5 (19%)
  • Seed 4 (15%)
  • Series C 3 (11%)
  • Series D 2 (7%)
See all 10 stages →

Country

  • United States 10 (37%)
  • United Kingdom 3 (11%)
  • Israel 2 (7%)
  • Canada 1 (4%)
  • Sweden 1 (4%)
See all 7 countries →

Investments

CompanyDescriptionRoundLinks
MioTech MioTech
MioTech is an artificial intelligence platform that empowers investment managers to better serve their clients in a world of complex data. By integrating and analyzing data from all types of sources, MioTech streamlines the entire investment process, creating an ultimate data-driven investing experience. MioTech has offices in Shanghai and HongKong.MioTech is backed by Horizons Ventures, ZhenFund, and prestigious individual investors around the world. Venture - Series Unknown / Jan 26, 2024
Fertilis Fertilis
Fertilis is a company that makes in vitro fertilization (IVF) less stressful and more successful for patients and clinicians. $2M / Seed / Jan 11, 2022
Catalog Catalog
Catalog is a developer of a data conversion and storage platform used to offer the next generation of digital data archives and computation. Its platform facilitates the encoding of data and information into DNA format and makes it economically attractive to use DNA as the major medium for long-term archival of data that enables customers to storedigital information in DNA molecules. It brings cutting-edge synthetic biology technologies to the world of information storage and computation.The company was founded in 2016 and is headquartered in Boston, Massachusetts. $35M / Series B / Sep 30, 2021
Owlstone Medical Owlstone Medical
Owlstone Medical focuses on creating breath-based diagnostic tools to enhance early detection of diseases such as cancer and respiratory conditions. The company's Breath Biopsy platform utilizes advanced technology to identify volatile organic compounds in breath, facilitating the discovery of non-invasive biomarkers. $57.9M / Series D / Sep 07, 2021
H2Pro H2Pro
H2Pro is a renewable energy company that is working on an efficient green hydrogen production method - E-TAC. Its mission is to enable the wide-scale adoption of sustainable hydrogen fuel by introducing a novel water-splitting technology. $22M / Series A / Dec 01, 2020
WELL Health Technologies WELL Health Technologies
WELL Health Technologies is the owner and operator of a portfolio of Primary Healthcare facilities. WELL Health Technologies is leveraging disruptive trends in the health and wellness space by strategically pursuing a proven blueprint M&A strategy in order to maximize profitable growth in the space. Target acquisition companies will be acrossvarious vertical industries within the health and wellness space and will possess low capital requirements and a high potential to exploit shifts in health trends. $17.6M / Post-IPO Equity / Sep 01, 2020
WELL Health Technologies WELL Health Technologies
WELL Health Technologies is the owner and operator of a portfolio of Primary Healthcare facilities. WELL Health Technologies is leveraging disruptive trends in the health and wellness space by strategically pursuing a proven blueprint M&A strategy in order to maximize profitable growth in the space. Target acquisition companies will be acrossvarious vertical industries within the health and wellness space and will possess low capital requirements and a high potential to exploit shifts in health trends. $7.9M / Post-IPO Debt / Mar 16, 2020
MioTech MioTech
MioTech is an artificial intelligence platform that empowers investment managers to better serve their clients in a world of complex data. By integrating and analyzing data from all types of sources, MioTech streamlines the entire investment process, creating an ultimate data-driven investing experience. MioTech has offices in Shanghai and HongKong.MioTech is backed by Horizons Ventures, ZhenFund, and prestigious individual investors around the world. Series A / Jan 06, 2020
Demetrix Demetrix
Demetrix manufactures natural medicines using synthesis biology. The company uses genetics and computing enabled deciphering technology to produce drugs. It enables refactoring biotechnology microbial hosts for gene synthesis. The company engineers strain to produce co-evolved and bio-inspired medicines and nutraceuticals.The company was foundedin 2015 and is headquartered in Emeryville, California. $50M / Series A / Jul 11, 2019
Owlstone Medical Owlstone Medical
Owlstone Medical focuses on creating breath-based diagnostic tools to enhance early detection of diseases such as cancer and respiratory conditions. The company's Breath Biopsy platform utilizes advanced technology to identify volatile organic compounds in breath, facilitating the discovery of non-invasive biomarkers. $35M / Oct 01, 2018
See all 27 investments →

Co-Investors

Horizons Ventures

About Horizons Ventures

VC Fund · Hong Kong, Hong Kong

Horizons Ventures focuses on investing in disruptive and technology-focused start-ups. The firm was founded in 1999 and is based in Hong Kong. Some of the latest exits are Skype, Siri, Facebook, Summly, and Waze.

Horizons Ventures Contacts

NameEmailPhoneSocials
Bart Swanson
Bart Swanson Advisor
Chris Liu
Chris Liu Special Projects
Patrick Poon
Patrick Poon Project Director
Debbie Chang
Debbie Chang Founder
Frances Kang
Frances Kang Director

Sign up to unlock verified contacts

Unlock Contacts
Open Horizons Ventures full profile

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Retail
Oil and Gas
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Fitness
Organic Food
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Blockchain
Facebook
B2B
Social Network
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Theatre
Medical
Recruiting
Web3
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Music
Art
Real Estate
Sporting Goods
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Burkina Faso
Oman
Puerto Rico
Poland
Cameroon
Guernsey
Sudan
Andorra
Colombia
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Moldova
Botswana
Seychelles
Paraguay
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
Canada
United States
United Kingdom
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Argentina
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Slovenia
Peru
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Li Ka-shing invest in?

Li Ka-shing invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series A and Series B stage. Most of the 27 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What is Li Ka-shing's check size?

Li Ka-shing typically joins rounds of $300k–$11M at Seed, $21M–$50M at Series A and $15M–$50M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Li Ka-shing participates in.

When did Li Ka-shing last invest?

The most recent investment recorded for Li Ka-shing closed in Jan 2024. Shizune tracks 27 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Li Ka-shing Li Ka-shing Find email